Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

Aimmune Therapeutics, Inc.. (2/28/19). "Press Release: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights". Brisbane, CA.

Organisations Organisation Aimmune Therapeutics Inc. (Nasdaq: AIMT)
  Group Aimmune Therapeutics (Group)
  Organisation 2 Nestlé Health Science S.A.
  Group Nestlé (Group)
Index term Index term Aimmune Therapeutics–Nestlé: investment, 201811 equity investment $98m w 3.24m shares at $30.27/share by Nestlé Health Science brings stake to 19%
Person Person Dallas, Jayson (Aimmune Therapeutics 201806– CEO before Ultragenyx + Roche + Novartis + Pfizer + P&G Pharma)
     


   
Record changed: 2019-04-01

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 650x65px

More documents for Aimmune Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75




» top